169 related articles for article (PubMed ID: 30201820)
1. Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.
Thakkar N; Green JA; Koh GCKW; Duparc S; Tenero D; Goyal N
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201820
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.
Edstein MD; Kocisko DA; Brewer TG; Walsh DS; Eamsila C; Charles BG
Br J Clin Pharmacol; 2001 Dec; 52(6):663-70. PubMed ID: 11736877
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.
Charles BG; Miller AK; Nasveld PE; Reid MG; Harris IE; Edstein MD
Antimicrob Agents Chemother; 2007 Aug; 51(8):2709-15. PubMed ID: 17517850
[TBL] [Abstract][Full Text] [Related]
4. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.
Vélez ID; Hien TT; Green JA; Martin A; Sharma H; Rousell VM; Breton JJ; Ernest TB; Rolfe K; Taylor M; Mohamed K; Jones SW; Chau NH; Hoa NT; Duparc S; Tan LK; Goyal N
Lancet Child Adolesc Health; 2022 Feb; 6(2):86-95. PubMed ID: 34871570
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.
Ayyoub A; Methaneethorn J; Ramharter M; Djimde AA; Tekete M; Duparc S; Borghini-Fuhrer I; Shin JS; Fleckenstein L
Antimicrob Agents Chemother; 2015 Dec; 60(3):1450-8. PubMed ID: 26666916
[TBL] [Abstract][Full Text] [Related]
6. A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study.
Bachhav SS; Taylor M; Martin A; Green JA; Duparc S; Rolfe K; Sharma H; Tan LK; Goyal N
Br J Clin Pharmacol; 2023 Mar; 89(3):1187-1197. PubMed ID: 36199201
[TBL] [Abstract][Full Text] [Related]
7. Tafenoquine: First Global Approval.
Frampton JE
Drugs; 2018 Sep; 78(14):1517-1523. PubMed ID: 30229442
[TBL] [Abstract][Full Text] [Related]
8. Tafenoquine: a promising new antimalarial agent.
Crockett M; Kain KC
Expert Opin Investig Drugs; 2007 May; 16(5):705-15. PubMed ID: 17461742
[TBL] [Abstract][Full Text] [Related]
9. Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.
Goyal N; Mohamed K; Rolfe K; Sahota S; Ernest T; Duparc S; Taylor M; Casillas L; Koh GCKW
AAPS J; 2018 Jun; 20(4):74. PubMed ID: 29869298
[TBL] [Abstract][Full Text] [Related]
10. Tafenoquine: the new kid on the block.
Chen V; Daily JP
Curr Opin Infect Dis; 2019 Oct; 32(5):407-412. PubMed ID: 31305490
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria.
Tenero D; Green JA; Goyal N
Antimicrob Agents Chemother; 2015 Oct; 59(10):6188-94. PubMed ID: 26248362
[TBL] [Abstract][Full Text] [Related]
12. Tafenoquine for travelers' malaria: evidence, rationale and recommendations.
Baird JK
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30380095
[TBL] [Abstract][Full Text] [Related]
13. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
[TBL] [Abstract][Full Text] [Related]
15. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
[TBL] [Abstract][Full Text] [Related]
16. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
17. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
[TBL] [Abstract][Full Text] [Related]
18. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria.
St Jean PL; Koh GCKW; Breton JJ; Espino FEJ; Hien TT; Krudsood S; Lacerda MVG; Llanos-Cuentas A; Lon C; Mohammed R; Namaik-Larp CS; Pereira DB; Saunders DL; Velez ID; Yilma D; Villegas MF; Duparc S; Green JA
Pharmacogenet Genomics; 2020 Sep; 30(7):161-165. PubMed ID: 32433338
[TBL] [Abstract][Full Text] [Related]
20. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
Warrasak S; Euswas A; Fukuda MM; Ittiverakul M; Miller RS; Krudsood S; Ohrt C
Int Ophthalmol; 2019 Aug; 39(8):1767-1782. PubMed ID: 30269312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
